Anti-IL-23 antibodies, compositions, methods and uses

Details Anti-IL-23 antibodies, compositions, methods and uses Anti-IL-23 antibodies, compositions, methods and uses

2009-02-13

2010-10-05

Mertz, Prema (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C536S023530, C435S325000, C435S320100, C435S252300

Reexamination Certificate

active

07807414

ABSTRACT:
An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

REFERENCES:
patent: 6060284 (2000-05-01), Bazan
patent: 6479634 (2002-11-01), Bazan
patent: 6495667 (2002-12-01), Bazan
patent: 6610285 (2003-08-01), Hirata
patent: 6632927 (2003-10-01), Adair et al.
patent: 6756481 (2004-06-01), Chirica et al.
patent: 6800460 (2004-10-01), Oppmann et al.
patent: 6835825 (2004-12-01), Bazan
patent: RE39015 (2006-03-01), Bazan et al.
patent: 7090847 (2006-08-01), Oppmann et al.
patent: 7183382 (2007-02-01), Oppmann et al.
patent: 7247711 (2007-07-01), Benson et al.
patent: 7252971 (2007-08-01), Benson et al.
patent: 7282204 (2007-10-01), Oft et al.
patent: 2003/0162261 (2003-08-01), Oppmann et al.
patent: 2004/0258686 (2004-12-01), Chirica et al.
patent: 2005/0208052 (2005-09-01), Katsikis et al.
patent: 2005/0244874 (2005-11-01), Kastelein et al.
patent: 2007/0048315 (2007-03-01), Presta
patent: WO 99/05280 (1999-02-01), None
patent: WO 99/40195 (1999-08-01), None
patent: WO 00/09552 (2000-02-01), None
patent: WO 00/53631 (2000-09-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 2004/042009 (2004-05-01), None
patent: WO 2004/058178 (2004-07-01), None
patent: WO 2004/071517 (2004-08-01), None
patent: WO 2004/081190 (2004-09-01), None
patent: WO 2004/101750 (2004-11-01), None
patent: WO 2007/024846 (2007-03-01), None
Oppmann, et al., “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12,” Immunity, 13: 715-725 (2000).
Peter J. Barnes, “Cytokine-directed therapies for the treatment of chronic airway diseases,” Cytokine & Growth Factor Reviews 14 (2003): 511-522 (2003).
Trinchieri, et al., “The IL-12 Family of Heterodimeric Cytokines: New Players in the Regulation of T Cell Responses,” Immunity, 19: 641-644 (2003).
Maguire van Seventer, et al., “Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EB13 in activated human dendritic cells,” Journal of Neuroimmunology, 133: 60-71 (2002).
Yadav, et al., “Cytokines and autoimmunity: redundancy defines their complex nature,” Current Opinion in Immunology, 15: 697-703 (2003).
Murphy, et al., “Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation,” Journal of Experimental Medicine, 198(12): 1951-1957 (2003).
David M. Frucht, “IL-23: A Cytokine That Acts on Memory T Cells,” Science STKE, 114: 1-3 (2002).
Wiekowski, et al., “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death,” Journal of Immunology, 166: 7563-7570(2001).
Belladonna, et al., “IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells,” The Journal of Immunology, 168: 5448-5454 (2002).
Parham, et al., “A Receptor for the Heterodimeric Cytokine IL-23 is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R,” The Journal of Immunology, 168: 5699-5708 (2002).
Cua, et al., “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” Nature, 421: 744-748 (2003).
GenBank Accession No. AF301620, Oppmann, et al., Dec. 4, 2000.
GenBank Accession No. AA418955, Hillier, et al., May 12, 1997.
GenBank Accession No. C06368, J. Takeda, Aug. 9, 1996.
GenBank Accession No. AA418747, Hillier, et al., May 12, 1997.
PCT International Search Report dated Sep. 5, 2007.
Panka, et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” Proceedings of the National Academy of Sciences USA, 85: 3080-3084 (1988).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Science USA, 79: 1979-1983 (1982).
Amit, et al., Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution, Science, 233(4765) :747-753 (1986).
Sehy, et al., “Unambiguous Detection of IL-23 (p19/p40) Protein in Native Samples Using a Novel Enzyme-Linked Immunosorbent Assay,” FASEB Journal, 19(4): A945-A946 (2005).
Supplementary European Search Report dated Jul. 20, 2009.

Affiliated with

Also associated with

Rating

Anti-IL-23 antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-IL-23 antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-23 antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4172418